1.Efficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial
Se Hyun KIM ; Do-Un JUNG ; Do Hoon KIM ; Jung Sik LEE ; Kyoung-Uk LEE ; Seunghee WON ; Bong Ju LEE ; Sung-Gon KIM ; Sungwon ROH ; Jong-Ik PARK ; Minah KIM ; Sung Won JUNG ; Hong Seok OH ; Han-yong JUNG ; Sang Hoon KIM ; Hyun Seung CHEE ; Jong-Woo PAIK ; Kyu Young LEE ; Soo In KIM ; Seung-Hwan LEE ; Eun-Jin CHEON ; Hye-Geum KIM ; Heon-Jeong LEE ; In Won CHUNG ; Joonho CHOI ; Min-Hyuk KIM ; Seong-Jin CHO ; HyunChul YOUN ; Jhin-Goo CHANG ; Hoo Rim SONG ; Euitae KIM ; Won-Hyoung KIM ; Chul Eung KIM ; Doo-Heum PARK ; Byung-Ook LEE ; Jungsun LEE ; Seung-Yup LEE ; Nuree KANG ; Hee Yeon JUNG
Psychiatry Investigation 2024;21(7):762-771
Objective:
This study was performed to evaluate the efficacy and safety of lurasidone (160 mg/day) compared to quetiapine XR (QXR; 600 mg/day) in the treatment of acutely psychotic patients with schizophrenia.
Methods:
Patients were randomly assigned to 6 weeks of double-blind treatment with lurasidone 160 mg/day (n=105) or QXR 600 mg/day (n=105). Primary efficacy measure was the change from baseline to week 6 in Positive and Negative Syndrome Scale (PANSS) total score and Clinical Global Impressions severity (CGI-S) score. Adverse events, body measurements, and laboratory parameters were assessed.
Results:
Lurasidone demonstrated non-inferiority to QXR on the PANSS total score. Adjusted mean±standard error change at week 6 on the PANSS total score was -26.42±2.02 and -27.33±2.01 in the lurasidone and QXR group, respectively. The mean difference score was -0.91 (95% confidence interval -6.35–4.53). The lurasidone group showed a greater reduction in PANSS total and negative subscale on week 1 and a greater reduction in end-point CGI-S score compared to the QXR group. Body weight, body mass index, and waist circumference in the lurasidone group were reduced, with significantly lower mean change compared to QXR. Endpoint changes in glucose, cholesterol, triglycerides, and low-density lipoprotein levels were also significantly lower. The most common adverse drug reactions with lurasidone were akathisia and nausea.
Conclusion
Lurasidone 160 mg/day was found to be non-inferior to QXR 600 mg/day in the treatment of schizophrenia with comparable efficacy and tolerability. Adverse effects of lurasidone were generally tolerable, and beneficial effects on metabolic parameters can be expected.
2.Survival of hypoxic human mesenchymal stem cells is enhanced by a positive feedback loop involving miR-210 and hypoxia-inducible factor 1.
Woochul CHANG ; Chang Youn LEE ; Jun Hee PARK ; Moon Seo PARK ; Lee So MAENG ; Chee Soon YOON ; Min Young LEE ; Ki Chul HWANG ; Yong An CHUNG
Journal of Veterinary Science 2013;14(1):69-76
The use of mesenchymal stem cells (MSCs) has emerged as a potential new treatment for myocardial infarction. However, the poor viability of MSCs after transplantation critically limits the efficacy of this new strategy. The expression of microRNA-210 (miR-210) is induced by hypoxia and is important for cell survival under hypoxic conditions. Hypoxia increases the levels of hypoxia inducible factor-1 (HIF-1) protein and miR-210 in human MSCs (hMSCs). miR-210 positively regulates HIF-1alpha activity. Furthermore, miR-210 expression is also induced by hypoxia through the regulation of HIF-1alpha. To investigate the effect of miR-210 on hMSC survival under hypoxic conditions, survival rates along with signaling related to cell survival were evaluated in hMSCs over-expressing miR-210 or ones that lacked HIF-1alpha expression. Elevated miR-210 expression increased survival rates along with Akt and ERK activity in hMSCs with hypoxia. These data demonstrated that a positive feedback loop involving miR-210 and HIF-1alpha was important for MSC survival under hypoxic conditions.
Cell Survival
;
Cobalt
;
Gene Expression Regulation/*physiology
;
Humans
;
Hypoxia-Inducible Factor 1, alpha Subunit/genetics/*metabolism
;
Mesenchymal Stromal Cells/drug effects/metabolism/*physiology
;
MicroRNAs/*metabolism
;
Oxygen/pharmacology
;
*Oxygen Consumption
;
RNA, Small Interfering/metabolism
3.In Vitro Antifungal Activity of Equol against Candida albicans.
Mycobiology 2010;38(4):328-330
In this study, we demonstrate that equol has fungicidal activities against Candida albicans. The minimum inhibitory and minimum fungicidal concentrations of equol against C. albicans were 516 and 1,032 microM, respectively. Two separate viability assays found that equol changed the integrity of the C. albicans cell membrane, possibly by formation of membrane lesions. Scanning electron microscopy demonstrated ultrastructural changes.
Candida
;
Candida albicans
;
Cell Membrane
;
Equol
;
Membranes
;
Microscopy, Electron, Scanning
4.In vitro Activity of Celery Essential Oil against Malassezia furfur.
Mycobiology 2009;37(1):67-68
Antifungal activity of celery essential oil against Malassezia furfur was investigated using broth microdilution and vapor contact methods. Potent antifungal activity was evident using both methods. Fungicidal activity was revealed in the vapor contact method.
Apium graveolens
;
Malassezia
5.In vitro Antifungal Activity of Limonene against Trichophyton rubrum.
Hee Youn CHEE ; Hoon KIM ; Min Hee LEE
Mycobiology 2009;37(3):243-246
In this study, the antifungal activities of limonene against Trichophyton rubrum were evaluated via broth microdilution and vapor contact assays. In both assays, limonene was shown to exert a potent antifungal effect against T. rubrum. The volatile vapor of limonene at concentrations above 1 microl/800 ml air space strongly inhibited the growth of T. rubrum. The MIC value was 0.5% v/v in the broth microdilution assay. The antifungal activity of limonene against T. rubrum was characterized as a fungicidal effect.
Cyclohexenes
;
Terpenes
;
Trichophyton
6.Multicenter Clinical Trials for Efficacy and Safety of Mirtazapine in Moderate-to-Severe Major Depressive Patients.
Yong Min AHN ; Kyu Young LEE ; Min Hee KANG ; Chul NA ; Seung Ho RHO ; Jin Wook SOHN ; Hyeon Gyun SON ; Bum Hee YU ; Kyung Kyu LEE ; Kwang Heun LEE ; Gi Chul LEE ; Sang Kyeong LEE ; Jong Hun LEE ; Chang Uk LEE ; Tae Youn JUN ; Sang Keun CHUNG ; Ik Seung CHEE ; Yong Sik KIM
Korean Journal of Psychopharmacology 2007;18(1):36-49
OBJECTIVE: The purpose of this study is to evaluate the efficacy and safety of mirtazapine treatment in multicenter population consisting of Korean patients suffering from moderate-to-severe depression. METHODS: Total 163 of in and outpatients with a diagnosis of major depressive disorder (DSM-IV) and 18 or over scores of 17-items Hamilton Rating Scale for Depression (HAMD) received treatment with mirtazapine (15-45 mg/day) for 6 weeks. Efficacy was assessed by HAMD, Montgomery and Asberg Depression Rating Scale (MADRS), Beck's Depression Inventory (BDI), and Clinical Global Impression (CGI) scales and statistical analyses were performed on the intent-to-treat sample (143 patients) using the last-observation-carried-forward method. In addition, reported adverse events, routine laboratory parameters, and vital signs were investigated to evaluate the safety of mirtazapine. RESULTS: Mean daily dose of mirtazapine was 28.4 mg. At the end of the study, the response rate (50% or more reduction from baseline in HAMD scores) was 75.5% and the remission rate (7 or less in HAMD score) was 42.7%. Mirtazapine treatment induced significant reduction in depressive symptoms at the 4(th) day and substantial reduction along the treatment period, as assessed by changes in HAMD, MADRS, BDI, and CGI scales. At the 4(th) day and first week of mirtazapine treatment, the mean HAMD-17 total score was significantly reduced compared that of the baseline and the response rates were 11.9% and 28.7%, respectively. Mirtazapine was well tolerated in general, and somnolence and sedation were the most common adverse events reported. In addition, there were no clinically relevant changes in laboratory parameters and vital signs, although body weight was increased. CONCLUSION: Although this trial had many limitations of open non-comparative study, mirtazapine was demonstrated to an effective treatment for moderate to severe major depressive disorder and was well tolerated. A potentially rapid onset of overall therapeutic efficacy of mirtazapine was suggested by significant changes in all major variables of efficacy after 4(th) day of treatment.
Body Weight
;
Depression
;
Depressive Disorder, Major
;
Diagnosis
;
Humans
;
Outpatients
;
Vital Signs
;
Weights and Measures
7.Antifungal Activity of Clove Essential Oil and its Volatile Vapour Against Dermatophytic Fungi.
Mycobiology 2007;35(4):241-243
Antifungal activities of clove essential oil and its volatile vapour against dermatophytic fungi including Candida albicans, Epidermophyton floccosum. Microsporum audouinii, Trichophyton mentagrophytes, and Trichophyton rubrum were investigated. Both clove essential oil and its volatile vapour strongly inhibit spore germination and mycelial growth of the dermatophytic fungi tested. The volatile vapour of clove essential oil showed fungistatic activity whereas direct application of clove essential oil showed fungicidal activity.
Candida albicans
;
Clove Oil
;
Epidermophyton
;
Syzygium*
;
Fungi*
;
Germination
;
Microsporum
;
Spores
;
Trichophyton
8.Antifungal Activity and Inhibitory Modes of Volatile Vapours of Essential Oils.
Mycobiology 2004;32(2):102-104
Antifungal activities of volatile vapours of essential oils were investigated. Volatile vapours of test essential oils except Cedar-wood and Pachouri showed inhibitory activity against test fungi. Volatile vapours of Birch essential oils exhibited fungistatic activity against dermatophytic filamentous fungi while others did fungicidal activity. Spores of dermatophytic filamentous fungi are more susceptible to volatile vapours of essential oils than mycelia.
Betula
;
Fungi
;
Oils, Volatile*
;
Spores
9.Isolation of Cryptococcus neoformans var. grubii (serotype A) from Pigeon Droppings in Korea.
Hee Youn CHEE ; Yoon Kyoung KIM
Mycobiology 2003;31(3):162-165
Three hundred and sixty five samples of avian droppings, collected from parks and zoo, were investigated for the occurrence of Cryptococcus neoformans in Korea. Thirteen samples were positive for C. neoformans. All isolates were obtained from withered pigeon droppings. Identification and serotyping of isolates were determined by means of serological test and polymerase chain reaction (PCR) fingerprinting. All isolates belonged to C. neoformans var. grubbi (serotype A).
Columbidae*
;
Cryptococcus neoformans*
;
Cryptococcus*
;
Dermatoglyphics
;
Korea*
;
Polymerase Chain Reaction
;
Serologic Tests
;
Serotyping
10.Fungistatic Activity of Kojic Acid Against Human Pathogenic Fungi and Inhibition of Melanin-production in Cryptococcus neoformans.
Mycobiology 2003;31(4):248-250
Kojic acid was investigated for its antifungal activity against the human pathogenic fungi including Candida albicans, Cryptococcus neoformans and Trichophyton rubrum. For C. albicans, C. neoformans and T. rubrum, the MIC (minimum inhibitory concentration) of kojic acid was 640, 80 and 160 microg/ml, respectively. In C. neoformans, melanin-producing yeast, kojic acid-treated nonmelanized cell was more susceptible to magainin than melanized cell, suggesting melanin give a protective function against microbial peptide.
Candida albicans
;
Cryptococcus neoformans*
;
Cryptococcus*
;
Fungi*
;
Humans*
;
Melanins
;
Trichophyton
;
Yeasts

Result Analysis
Print
Save
E-mail